Mark Enyedy

Insider profile

Currently holds positions in LogicBio Therapeutics Inc, Akebia Therapeutics Inc and ImmunoGen Inc

Performance

Overall performance
2.5

Performance over holding periods
2.5
30 days 90 days 120 days
Average return 8% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
4 0% Buy
34 71% Buy
47 69% Buy

Positions

Position Company Period
Director LogicBio Therapeutics Inc March 17, 2020 -
Independent Director Akebia Therapeutics Inc Dec. 12, 2018 -
President, Chief Executive Officer, Director ImmunoGen Inc May 16, 2016 -
Independent Director Keryx Biopharmaceuticals Inc Sept. 11, 2017 - Dec. 12, 2018
Independent Director Fate Therapeutics Inc July 1, 2012 - May 2, 2018
Director Proteostasis Therapeutics Inc June 30, 2014 - Jan. 1, 2015
Chief Executive Officer, Director Proteostasis Therapeutics Inc None -

Mark Enyedy's trades of ImmunoGen Inc's stock


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value
Number of shares Price Value Details
2024-02-06 2024-02-05 PlS Planned sale
76,957 -10.9%
393.71
US$2,855,977
76,957 -10.9% 393.71 US$2,855,977
2024-02-05 2024-02-05 PrS Proposed sale
38,606
375.11
US$1,126,510
38,606 375.11 US$1,126,510
2023-08-04 2023-08-04 PrS Proposed sale
22,471
79.96
US$4,871,775
22,471 79.96 US$4,871,775
2023-08-04 2023-08-04 S Sale
992,397 -64.2%
16.96
US$16,831,053
992,397 -64.2% 16.96 US$16,831,053
2023-08-04 2023-08-03 S Sale
1,020,000 -69.8%
16.61
US$16,942,200
1,020,000 -69.8% 16.61 US$16,942,200
2023-08-03 2023-08-03 PrS Proposed sale
1,020,000
16.61
US$16,938,477
1,020,000 16.61 US$16,938,477
2023-08-04 2023-08-02 S Sale
8,636 -1.9%
18.15
US$156,743
8,636 -1.9% 18.15 US$156,743
2023-08-04 2023-08-02 S Sale
986,521 -68.7%
17.45
US$17,214,791
986,521 -68.7% 17.45 US$17,214,791
2023-08-02 2023-08-02 PrS Proposed sale
995,157
17.45
US$17,367,363
995,157 17.45 US$17,367,363
2020-02-25 2020-02-24 PlS Planned sale
55,222 -11.3%
4.99
US$275,558
55,222 -11.3% 4.99 US$275,558
2019-02-25 2018-02-22 PlS Planned sale
51,070 -9.5%
5.60
US$285,992
51,070 -9.5% 5.60 US$285,992